Vaccines Articles
Researchers at the La Jolla Institute for Allergy and Immunology have found individuals who had been inoculated with the newer pertussis (whooping cough) vaccine as part of their initial series of shots mount a weaker recall response when receiving booster shots later on.
The Centers for Disease Control andPrevention is warning about a shortage of Shringrix, the newest shingles vaccine recommended for individuals 50 years and older, due to greater-than-expected demand.
FDA's Vaccines and Related Biological Products Advisory Committee chose the Northern Hemisphere’s 2018-19 influenza (flu) vaccine strains based on the World Health Organization’s recommendations.
A recent meta-analysis of six studies of mumps vaccine effectiveness conducted in the U.S. found protection against mumps lasts an average of 27 years after the last dose of the vaccine.
The Centers for Disease Control and Prevention advisory committee has voted 12-2 to recommend FluMist, the nasal spray version of the influenza vaccine, be used during the 2018-19 influenza (flu) season.
A study examined whether the vaccine schedule was associated with an increased risk of infections not targeted by vaccines and found no statistically significant differences in estimated cumulative vaccine antigen exposure through the first 23 months of life.
The World Health Organization is recommending a single dose of the typhoid conjugate vaccine for use in infants and children older than 6 months and a catch-up vaccine in children up to 15 years in countries where the infection is endemic.
An Internet panel survey of healthcare personnel (HCP) showed the overall influenza vaccination coverage estimate among HCP was 78.6 percent in the 2016-17 season, an increase of 15 percentage points since the 2010-11 season, but similar to the 2013-14 through 2015-16 seasons, with the highest coverage among those whose workplace had vaccination requirements.
Grifols’ HyperRAB (rabies immune globulin [human]) has been approved by the U.S. Food and Drug Administration to treat rabies postexposure prophylaxis.
Researchers at the University of Oxford have begun a two-year clinical trial to test a universal influenza (flu) vaccine in more than 2,000 patients.
With many reports about this year’s influenza (flu) vaccine ineffectiveness, a new study shows it is more effective than thought, especially among children.
Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.
